Voyager Therapeutics, Inc. (NASDAQ:), a company specializing in biological products, has reported a recent transaction by Chief Operating Officer Robin Swartz. According to the latest regulatory filings, Swartz sold 1,357 shares of common stock at an average price of $9.88, totaling over $13,000.
The transaction occurred on April 2, 2024, and was not a discretionary trade by Swartz. Instead, it was executed pursuant to a durable automatic sales instruction letter to cover tax withholding obligations related to the vesting of restricted stock units. The sales were made at varying prices, ranging from $9.83 to $10.01 per share.
Following the transaction, Swartz continues to hold 117,004 shares of Voyager Therapeutics, indicating a remaining substantial interest in the company’s performance. The transaction details were provided in a Form 4 filing with the Securities and Exchange Commission, with the weighted average price reflecting the range of prices at which the stock was sold.
Investors often monitor insider transactions as they can provide insights into the executives’ perspectives on the company’s value and future prospects. However, as this sale was related to tax obligations, it may not necessarily reflect Swartz’s outlook on Voyager Therapeutics’ potential or current valuation.
For further information regarding the specific prices at which the shares were sold within the reported range, the filing noted that Swartz has agreed to provide full details to Voyager Therapeutics or the SEC staff upon request. The sale was signed off by Scott MacDonald, acting as Attorney-in-Fact for Robin Swartz.
InvestingPro Insights
Voyager Therapeutics, Inc. (NASDAQ:VYGR) has recently been under the investor’s microscope after the insider transaction by the company’s Chief Operating Officer. To provide further context to the company’s financial health and future prospects, here are some InvestingPro Insights that may be of interest to shareholders and potential investors.
The company boasts a robust balance sheet, as indicated by one of the InvestingPro Tips, with Voyager Therapeutics holding more cash than debt. This positions the company well in terms of financial stability and may provide some reassurance to investors concerned about the recent insider selling for tax purposes.
Another InvestingPro Tip reveals that two analysts have revised their earnings upwards for the upcoming period, suggesting a potential positive outlook on the company’s performance. This contrasts with the anticipated sales decline and expected drop in net income for the current year, as noted by analysts.
Turning to real-time metrics from InvestingPro, Voyager Therapeutics presents an attractive valuation with a Price to Earnings (P/E) Ratio of 3.06, which adjusts to 3.81 for the last twelve months as of Q4 2023. The company’s Revenue Growth has been impressive, with a staggering 511.16% increase over the last twelve months as of Q4 2023. Additionally, the company’s stock has experienced a significant price uptick of 40.57% over the last six months, which may capture the attention of growth-oriented investors.
For investors seeking to delve deeper into Voyager Therapeutics’ financials and future projections, additional InvestingPro Tips are available. There are currently 9 more tips listed on InvestingPro, which can be accessed at: https://www.investing.com/pro/VYGR. To make this premium financial analysis tool even more accessible, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
